Trials / Terminated
TerminatedNCT05127811
A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma
A Phase I Dose Escalation Study of ZN-d5 Monotherapy in Chinese Subjects With Non-Hodgkin Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Zentera Therapeutics HK Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase I dose-escalation, open-label, multicenter study to assess the safety, tolerability, clinical activity, and pharmacokinetics (PK) of ZN-d5 in Chinese subjects with non-Hodgkin lymphoma (NHL).
Detailed description
For the Phase I dose escalation study of ZN-d5, it is planned that after the starting dose, subsequent dose assignments will be made by means of a model-assisted design, until the MTD or RP2D is determined in the Chinese population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZN-d5 | BION design |
Timeline
- Start date
- 2021-10-21
- Primary completion
- 2023-05-26
- Completion
- 2023-05-26
- First posted
- 2021-11-19
- Last updated
- 2023-06-02
Locations
3 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05127811. Inclusion in this directory is not an endorsement.